MARKET

IKT

IKT

Inhibikase Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.62
+0.02
+0.36%
Closed 16:00 04/09 EDT
OPEN
5.60
PREV CLOSE
5.60
HIGH
5.69
LOW
5.60
VOLUME
11.29K
TURNOVER
--
52 WEEK HIGH
11.80
52 WEEK LOW
5.12
MARKET CAP
54.00M
P/E (TTM)
-16.2287
1D
5D
1M
3M
1Y
5Y
Inhibikase Therapeutics reports Q4 results
Inhibikase Therapeutics (IKT): Q4 GAAP EPS of -$0.15.Cash and cash equivalents of $13.95MPress Release
Seekingalpha · 04/01 12:49
Inhibikase Therapeutics 4Q Loss/Shr 15c >IKT
Inhibikase Therapeutics 4Q Loss/Shr 15c >IKT
Dow Jones · 04/01 12:02
Inhibikase Therapeutics 4Q Rev $170,416 >IKT
Inhibikase Therapeutics 4Q Rev $170,416 >IKT
Dow Jones · 04/01 12:02
Press Release: Inhibikase Therapeutics Reports -2-
Dow Jones · 04/01 12:00
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) and related disorders inside and outside of the brain, today reported financial results for the fo...
PR Newswire · 04/01 12:00
-- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts Q4 Revenue $170,416
MT Newswires · 04/01 08:14
10-K: INHIBIKASE THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/31 18:16
The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 25)
Benzinga · 03/26 11:28
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IKT. Analyze the recent business situations of Inhibikase Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About IKT
Inhibikase Therapeutics Inc. is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s lead product candidate, IkT-148009 is for the treatment of PD, and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009, is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. The Company’s products candidate also include IKT-001Pro, which is a prodrug of the anticancer agent Imatinib, and used as a treatment for stable-phase chronic myelogenous leukemia (CML), and IKT-01427 for progressive multifocal leukoencephalopathy (PML).

Webull offers kinds of Inhibikase Therapeutics Inc stock information, including NASDAQ:IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.